Prostate-specific Membrane Antigen Targeted Prostate Imaging and Therapy
作者
Gurvinder Kaur,Piyush Aggarwal,Jaya Shukla,Harmandeep Singh,Bhagwant Rai Mittal
出处
期刊:Royal Society of Chemistry eBooks [Royal Society of Chemistry] 日期:2025-06-04卷期号:: 278-293
标识
DOI:10.1039/9781837677139-00278
摘要
Prostate cancer (PCa) is the second most prevalent malignancy in the world. Nuclear medicine plays a pivotal role in the management of patients with PCa. The excellent results of the OSPREY, CONDOR and ProPSMA trials paved the way for the Food and Drug Administration (FDA) approval of 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyl) and [68Ga]Ga–N,N′-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid (HBED-cc)–prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET) agents for diagnostic use in PCa. The VISION trial showed the success of [177Lu]Lu–1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)–PSMA-617 targeted therapy in improving the progression-free and overall survival in metastatic castration-resistant PCa, leading to its FDA approval in 2022. The theranostic approach involves targeting a transmembrane (Type II) receptor comprising two small domains of 19 amino acids (intracellular) and 24 amino acids (transmembrane) and a large extracellular domain of 707 amino acids. PSMA exhibits overexpression in PCa. Consequently, radiolabeled PSMA ligands (antibodies or peptides) using various radionuclides (111In, 99mTc, 68Ga, 18F, 89Zr, 177Lu, 225Ac) serve a dual purpose, the diagnosis and therapy of primary and metastatic PCa. In this chapter, the fundamental radiochemistry, biodistribution patterns, dosimetry and clinical applications of radiopharmaceuticals are explained in detail.